Equities

Amrutanjan Health Care Ltd

AMRUTANJAN:NSI

Amrutanjan Health Care Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)801.50
  • Today's Change20.50 / 2.62%
  • Shares traded31.12k
  • 1 Year change+27.20%
  • Beta1.0572
Data delayed at least 15 minutes, as of Sep 20 2024 11:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amrutanjan Health Care Limited is an India-based company, which is engaged in the business of manufacturing, supplying and sale of products in pain management, congestion management, beverages, and hygiene and services in pain management. Its segments include OTC Products, Women Hygiene, Beverages and Others. The OTC Products segment is engaged in manufacturing products for pain management, congestion management and hygiene. The Women Hygiene includes Comfy Snug Fit, Comfy Snug Fit Extra Long, and Comfy Snug Fit Ultra XL. The Beverages segment is engaged in manufacturing fruit juices and oral hydration drinks. The Others segment includes the pain management center. The Company’s pain management products include Pain Balm Extra Power, Strong Pain Balm, New Maha Strong Pain Balm, Roll on and Advanced Back Pain + Roll-On, among others. Its congestion management products include Relief Cold Rub, Relief Nasal Inhaler, Relief Cough Syrup and Relief Swas Mint.

  • Revenue in INR (TTM)4.27bn
  • Net income in INR425.73m
  • Incorporated1936
  • Employees635.00
  • Location
    Amrutanjan Health Care LtdNEW NO.103, OLD NO. 42-45LUZ CHURCH ROADMYLAPORECHENNAI 600004IndiaIND
  • Phone+91 4 424994465
  • Fax+91 4 424994585
  • Websitehttps://www.amrutanjan.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lincoln Pharmaceuticals Ltd5.92bn979.63m14.57bn1.70k14.87--13.342.4648.9148.91295.69--------3,483,600.00--13.95--16.5451.9250.6516.5414.71--60.93--3.4413.769.6627.9913.8821.543.71
Kopran Ltd6.37bn592.79m15.61bn358.0022.29--21.442.4514.5314.53150.01--------17,794,040.00--8.47--12.2336.0332.939.318.89--27.17--25.4111.5411.4287.1116.2312.53--
JG Chemicals Ltd-100.00bn-100.00bn16.17bn56.00-------------------------------------------------14.90---43.84------
Beta Drugs Ltd2.96bn364.37m16.48bn315.0045.2210.4935.655.5737.9037.90307.60163.431.314.514.17--16.1015.1023.9122.2338.7339.7712.3212.381.5117.810.0654--30.2135.0118.6235.29-10.89--
Zota Health Care Ltd1.98bn-242.34m16.59bn445.00----3,553.168.37-9.27-9.2776.32--------4,452,605.00---1.38---1.8549.8635.95-12.23-1.33---2.87----28.9616.08-148.54--39.850.00
Windlas Biotech Ltd6.61bn596.01m17.97bn1.15k30.14--23.632.7228.5228.52316.58--------5,730,702.00--------37.39--9.01----48.16----22.97--36.51------
Sigachi Industries Ltd4.10bn594.65m18.18bn991.0034.00--25.554.431.601.6010.97--------4,136,886.00--14.77--19.5752.3350.3014.4314.92--7.19--1.6132.0825.3431.3424.6470.35--
Hester Biosciences Ltd2.99bn193.56m20.17bn642.00101.92--53.286.7523.2623.26350.03--------4,656,698.00--6.15--7.6971.5266.647.3412.83--2.26--23.2714.4511.33-29.06-14.591.49-11.42
Panacea Biotec Ltd5.46bn-279.53m20.25bn1.15k----266.613.71-4.58-4.5889.84--------4,761,763.00--10.26--16.5360.2450.27-5.2024.87---17.30--0.0021.574.1396.47--74.65--
Syncom Formulations (India) Ltd2.91bn285.50m20.94bn802.0068.35--62.577.200.3260.3262.99--------3,626,019.00--7.50--10.2339.5334.109.829.38--7.67----17.457.1226.1317.95----
Amrutanjan Health Care Ltd4.27bn425.73m22.57bn635.0053.12--46.235.2814.7114.71147.56--------6,726,040.00--16.22--20.1249.6153.099.9713.23--212.51--18.9510.9610.7112.9012.4626.9316.43
Themis Medicare Ltd4.08bn500.16m23.77bn1.54k47.57--38.575.835.435.4344.31--------2,648,322.00--11.12--16.4663.5160.3212.2614.96------7.597.7415.75-23.51--26.73--
IOL Chemicals and Pharmaceuticals Ltd.20.72bn1.19bn28.29bn2.78k23.86--15.301.3720.2020.20353.05--------7,461,253.00--14.91--19.4533.9634.545.7212.00--10.06--10.59-3.804.82-3.39-10.7035.27--
Dishman Carbogen Amcis Ltd24.16bn-2.48bn28.62bn1.13k----165.731.18-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
SMS Pharmaceuticals Ltd7.38bn569.64m30.22bn1.20k52.89--33.964.096.756.7587.48--------6,168,549.00--5.43--7.3330.1233.307.697.87--4.21--6.1735.868.81805.824.478.419.86
Data as of Sep 20 2024. Currency figures normalised to Amrutanjan Health Care Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

7.71%Per cent of shares held by top holders
HolderShares% Held
DSP Asset Managers Pvt. Ltd.as of 31 Aug 20241.47m5.02%
Sundaram Asset Management Co. Ltd.as of 31 Aug 2024484.54k1.66%
Alquity Investment Management Ltd.as of 31 Jul 2024130.50k0.45%
Dimensional Fund Advisors LPas of 05 Sep 202485.77k0.29%
ICICI Prudential Asset Management Co. Ltd.as of 31 Aug 202446.80k0.16%
Matthews International Capital Management LLCas of 06 Sep 202423.92k0.08%
SSgA Funds Management, Inc.as of 05 Sep 202411.64k0.04%
American Century Investment Management, Inc.as of 05 Sep 20242.92k0.01%
DFA Australia Ltd.as of 31 Jul 2024413.000.00%
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.